Lidocaine + prilocaine

Generic name
Lidocaine + prilocaine
Brand name
ATC Code
N01BB20
Compare …

Lidocaine + prilocaine

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

EMLA (Local anaesthesia)
  • Cutaneous
    • 0 months up to 3 months

      • Cream: apply max. 1 g on a maximum of 10 cm² on intact skin under occlussion, for a maximum of 1 hour. Maximum 1 dose per 24 hours.
        Patches: apply max 1 plaster per 24 hours, for a maximum of 1 hour. 

         

    • 3 months up to 12 months

      • Cream: apply a max. 2 g on a maximum of 20 cm² on the intact skin under occlusion for a maximum of 1 hour. Maximum 2 doses per 24 hours with a 12 hour interval between doses.
        Patch: apply  a maximum of 2 patches per dose for 1 hour. Maximum 2 doses per 24 hours.



    • 1 year up to 6 years

      • Cream: Apply max. 10 g on a maximum of 100 cm² on the intact skin under occlusion. Remove after 1 hour (max 5 hours).
        Patch: Apply a maximum of 10 patches at the same time. Remove after 1 hour (max. 5 hours).



    • 6 years up to 12 years

      • Cream: Apply max. 20 g on a maximum of 200 cm² on in tact skin under occlusion. Remove after 1 hour (max 5 hours).
        Patch: Apply a maximum of 20 patches at the same time. Remove after 1 hour (max 5 hours).



    • 12 years up to 18 years

      • Cream: Apply 1.5-2 g per 10 cm² on in tact skin under occlusion. Remove after 1 hour (max. 5 hours).
        Patch: Apply one or more patches and remove after 1 hour (max. 5 hours).

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Methaemoglobinaemia is observed more frequently in neonates and infants, often due to overdosing.

Purpura, petechiae (especially after longer application times in children with atopic dermatitis or mollusca contagiosa)

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

Premature infants and children aged under 12 months treated with drugs that may induce methaemoglobinaemia.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Lidcaine+prilocaine (Emla):
Due to the risk of increased methaemoglobin levels, do not use in preterm infants with a gestational age < 37 weeks or on the genitals of children younger than 12 years; sufficient efficacy in circumcision and heel prick has not been demonstrated. Due to its size, the patch is less suitable for certain body parts of children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANESTHETICS, LOCAL

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Amides
N01BB08
N01BB01
N01BB10
N01BB02
N01BB52
N01BB52
N01BB03
N01BB04
N01BB09
Esters of benzoic acid
N01BC01
ESTERS OF BENZOIC ACID
N01BC01

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Aspen Pharma Trading Limited, SmPC EMLA (RVG 11015/15721) 03-12-2021, www.geneesmiddeleninformatiebank.nl
  3. Eurocept International BV,, SmPC Rapydan (RVG 100315) 26-12-2011, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose